Retatrutide: The Triple Agonist GLP-1 Drug Explained

If the trajectory of weight-loss medicine over the past decade has felt like a steady upward climb, retatrutide feels like someone strapped a rocket to the ascent. Developed by Eli Lilly under the research code LY3437943, this investigational drug is the first triple-receptor agonist in clinical trials — hitting the GLP-1, GIP, and glucagon receptors simultaneously. Phase 3 results from late 2025 showed average body weight loss of 28.7% at 68 weeks, the highest figure ever recorded for a pharmacological obesity treatment in a Phase 3 trial.

But what exactly is retatrutide, how does the triple mechanism work, and when can patients actually access it? This guide covers everything the current evidence tells us.

What Is Retatrutide?

Retatrutide is a synthetic peptide hormone agonist developed by Eli Lilly and Company. It is administered as a once-weekly subcutaneous injection and has a half-life of approximately six days — consistent with the weekly dosing schedules used by semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound).

What sets retatrutide apart is the breadth of its receptor targeting. Where semaglutide acts on one receptor (GLP-1) and tirzepatide acts on two (GLP-1 and GIP), retatrutide acts on three:

• GLP-1 (glucagon-like peptide-1)
• GIP (glucose-dependent insulinotropic polypeptide)
• Glucagon receptor (GCG)

This triple-agonism is what researchers and clinicians believe explains the drug's exceptional efficacy — and understanding each receptor's role helps illustrate why.

How the Triple Mechanism Works

GLP-1 Receptor Agonism

GLP-1 is the receptor pathway that launched the modern weight-loss drug revolution. When activated, it slows gastric emptying (making you feel full longer), suppresses appetite in the brain, and stimulates insulin release in a glucose-dependent manner. Semaglutide — the active ingredient in Ozempic and Wegovy — works almost entirely through this pathway.

GIP Receptor Agonism

GIP was initially viewed as a minor player, but tirzepatide's success showed that adding GIP agonism on top of GLP-1 produces significantly better weight loss results. GIP receptors are found throughout the brain, fat tissue, and gut, and appear to synergize with GLP-1 to amplify appetite suppression and improve fat metabolism. Retatrutide is notably more potent at the GIP receptor than at either GLP-1 or glucagon — roughly 8.9 times more potent than the body's native GIP ligand, with an EC50 of 0.0643 nM.

Glucagon Receptor Agonism

This is the truly novel addition. Glucagon traditionally acts to raise blood sugar — which sounds counterproductive for a weight-loss or diabetes drug. But glucagon receptor agonism, when combined with the insulin-sensitizing effects of GLP-1 and GIP, appears to dramatically increase energy expenditure and accelerate fat oxidation, particularly in the liver. This is likely why retatrutide has shown extraordinary results for metabolic-associated liver disease in addition to obesity.

The molecule's unique helical structure allows it to engage the transmembrane domain of GLP-1 receptors with its N-terminal segment while simultaneously interacting with GIP receptor extracellular loops — a pharmacological engineering feat that enables all three signals to be delivered in a single weekly injection.

Clinical Trial Results

Phase 2 Obesity Trial (NEJM, 2023)

The landmark Phase 2 trial published in the New England Journal of Medicine enrolled adults with obesity (without type 2 diabetes) and treated them for 48 weeks. Results were striking:

• 12 mg dose: 24.2% mean body weight reduction
• 8 mg dose: 22.8% mean body weight reduction
• Placebo: approximately 2.1% weight reduction

At the time, these were the highest weight-loss figures ever reported for a pharmacological trial of this length.

Phase 2 Liver Disease Trial (Nature Medicine, 2024)

A separate Phase 2a trial published in Nature Medicine examined retatrutide in adults with metabolic dysfunction-associated steatotic liver disease (MASLD). The liver fat reductions were extraordinary:

• 1 mg: −42.9% relative reduction in liver fat
• 4 mg: −57.0%
• 8 mg: −81.4%
• 12 mg: −82.4%
• Placebo: +0.3%

Over 85% of participants in the higher-dose groups achieved complete resolution of hepatic steatosis — a disease with few effective treatments affecting roughly 25% of the global population.

Phase 3 TRIUMPH-4 Trial (December 2025)

Eli Lilly announced topline results from TRIUMPH-4 in December 2025 — the first Phase 3 trial from the broader TRIUMPH program to report. This study enrolled adults with obesity or overweight and knee osteoarthritis (without type 2 diabetes), and treated them for 68 weeks:

• 12 mg dose: 28.7% mean body weight loss
• 9 mg dose: 26.4% mean body weight loss
• Average absolute weight loss: 71.2 lbs on the highest dose

These figures represent the highest weight-loss results ever recorded in a Phase 3 randomized controlled trial for any obesity medication — and the trial also showed substantial relief from osteoarthritis knee pain, opening a potential new indication beyond metabolic disease.

Retatrutide vs. Semaglutide vs. Tirzepatide

Direct head-to-head trials between the three drugs have not yet been published, but cross-trial comparisons tell a clear story:

The progression from single to dual to triple agonism correlates almost linearly with increasing weight-loss efficacy. Each additional receptor pathway contributes meaningfully rather than redundantly.

The critical caveat: retatrutide is not yet FDA-approved, and patients cannot currently access it outside of clinical trials. Semaglutide and tirzepatide are available today and produce clinically meaningful, life-changing results for most patients who tolerate them.

Side Effects and Safety Profile

Retatrutide's adverse event profile closely mirrors that of other GLP-1-class drugs, with gastrointestinal side effects dominating at higher doses. From the Phase 3 TRIUMPH-4 trial:

• Nausea: 38.1% (9 mg) / 43.2% (12 mg) vs. 10.7% placebo
• Diarrhea: 34.7% / 33.1% vs. 13.4% placebo
• Constipation: 21.8% / 25.0% vs. 8.7% placebo
• Vomiting: 20.4% / 20.9% vs. 0.0% placebo
• Decreased appetite: 19.0% / 18.2% vs. 9.4% placebo

These side effects are predominantly mild-to-moderate and transient, typically concentrated during the dose-escalation phase. They generally improve as the body acclimates to the drug. The same GI tolerability strategies used with semaglutide and tirzepatide — slow titration, smaller meals, avoiding high-fat foods during ramp-up — are expected to apply.

Like other GLP-1-class medications, retatrutide carries a theoretical risk of thyroid C-cell tumors based on rodent models (the same black-box warning applied to semaglutide and tirzepatide). It is contraindicated in individuals with personal or family history of medullary thyroid carcinoma or MEN2 syndrome. Longer-term cardiovascular outcome data from Phase 3 trials are still forthcoming.

Investigational Dosing

Retatrutide has been studied in Phase 3 primarily at 9 mg and 12 mg once-weekly subcutaneous doses, with careful dose escalation protocols used to reach the maintenance dose. Starting low (typically 2 mg in trials) and stepping up over several months allows the body to adapt and minimizes GI side effects.

The half-life of approximately six days means steady-state plasma concentrations are reached after about four to five weeks at any given dose level. This pharmacokinetic profile supports weekly dosing and smooth concentration-response behavior.

Important: Retatrutide is not approved for prescription use. Dosing described here reflects investigational trial protocols only and should not be used as guidance for any off-label or compounded product.

Beyond Weight Loss: Emerging Applications

The TRIUMPH Phase 3 program spans multiple disease states, and early data suggests retatrutide's therapeutic potential extends well beyond obesity:

• Type 2 Diabetes: Multiple TRIUMPH trials evaluating glycemic control, with data expected through 2026
• Metabolic Liver Disease (MASLD/MASH): Phase 2 data showing >80% liver fat reduction at therapeutic doses represents a potential breakthrough for a disease with few effective options
• Osteoarthritis: TRIUMPH-4 showed substantial knee pain reduction, likely driven by weight-loss reducing mechanical joint load
• Cardiovascular Disease: CVOT data expected to build on the cardiometabolic benefits already established across the GLP-1 drug class

FDA Approval Timeline and Availability

As of April 2026, retatrutide is not FDA-approved and remains an investigational drug. The current expected timeline:

• Phase 3 data readouts: Seven TRIUMPH trials underway, most expected to report in 2026
• NDA submission: Expected Q4 2026 – Q1 2027
• FDA review period: Approximately 10–12 months from NDA acceptance
• FDA approval: Estimated late 2027 – Q1 2028
• Commercial launch: Projected Q1–Q2 2028

For patients who cannot wait, semaglutide and tirzepatide remain available today through licensed prescribers. Retatrutide compounding would face significant regulatory constraints as a non-approved drug substance.

The Bottom Line

Retatrutide represents a genuine step-change in obesity pharmacology. Its triple-receptor mechanism translates directly into clinical outcomes: Phase 3 trials have confirmed weight loss approaching 29% of body weight — roughly double what was achievable with first-generation GLP-1 drugs just a few years ago, and meaningfully above the already-impressive results seen with tirzepatide.

The caveat that matters most right now: retatrutide is not available. For the foreseeable future — likely until late 2027 at the earliest — it remains a compelling clinical story rather than a prescription option. Patients seeking treatment today should work with a knowledgeable clinician to evaluate semaglutide or tirzepatide, both of which produce life-changing results in their own right.

What retatrutide signals is a future where obesity is routinely treated to near-surgical weight-loss levels with a once-weekly injection. That future is now measured in months, not decades.